Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

5.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.4K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanistic insights into emerging therapeutic platforms: The 72<sup>nd</sup> annual Montagna Symposium on the Biology of Skin.

The Journal of investigative dermatology·2026
Same author

ESPRESSO: spatiotemporal omics based on organelle phenotyping.

Nature methods·2025
Same author

Spatial and Single-Cell Transcriptomics Reveal Keratinocytes as Key Players in Vulvar Lichen Sclerosus Pathogenesis.

The Journal of investigative dermatology·2025
Same author

Comprehensive secretome profiling and CRISPR screen identifies SFRP1 as a key inhibitor of epidermal progenitor proliferation.

Cell death & disease·2025
Same author

A spatiotemporal and machine-learning platform facilitates the manufacturing of hPSC-derived esophageal mucosa.

Developmental cell·2025
Same author

Diversity of human skin three-dimensional organotypic cultures.

Current opinion in genetics & development·2024

Related Experiment Video

Updated: Apr 27, 2026

Cell Population Analyses During Skin Carcinogenesis
06:53

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

15.5K

Advanced treatment for basal cell carcinomas.

Scott X Atwood1, Ramon J Whitson1, Anthony E Oro1

  • 1Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California 94305.

Cold Spring Harbor Perspectives in Medicine
|July 3, 2014
PubMed
Summary

Basal cell carcinomas (BCCs) are common skin cancers. While vismodegib targets the Hedgehog pathway, drug resistance necessitates developing new antagonists for advanced BCC treatment.

More Related Videos

Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.2K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

20.5K

Related Experiment Videos

Last Updated: Apr 27, 2026

Cell Population Analyses During Skin Carcinogenesis
06:53

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

15.5K
Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.2K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

20.5K

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Basal cell carcinomas (BCCs) are frequent epithelial cancers reliant on the Hedgehog signaling pathway for growth.
  • Current treatments like surgical excision are effective for most sporadic BCCs, but advanced or metastatic cases require improved options.

Purpose of the Study:

  • To review current Basal cell carcinoma treatment modalities.
  • To discuss the development of next-generation Hedgehog antagonists for BCC.

Main Methods:

  • Literature review of existing Basal cell carcinoma therapies.
  • Analysis of Hedgehog pathway inhibitors and their mechanisms.
  • Discussion of emerging therapeutic strategies targeting downstream components.

Main Results:

  • Vismodegib, a Smoothened antagonist, is effective but faces challenges with drug resistance.
  • Drug resistance in BCC highlights the need for novel therapeutic targets.
  • Next-generation antagonists targeting downstream Hedgehog pathway components are under development.

Conclusions:

  • Improved treatment strategies are crucial for advanced and metastatic Basal cell carcinomas.
  • Targeting downstream components of the Hedgehog pathway offers a promising avenue for overcoming drug resistance.
  • Further research into novel antagonists is essential for effective BCC management.